https://www.business-standard.com/article/international/moderna-vaccine-100-effective-in-severe-cases-to-seek-us-eu-approval-120120100047_1.html
The primary analysis, which included 196 cases, found the vaccine was 94.1 per cent effective, in line with preliminary findings released earlier this month. None of the participants in the trial who’d received the vaccine developed severe Covid-19. All 30 severe cases observed in the study occurred in participants who received placebo shots, according to a company statement. The shares extended their gains to as much as 12 per cent before US markets opened, hitting a record of $142.85. They have risen more than sixfold since the year began.
